Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Ticker SymbolRYTM
Company nameRhythm Pharmaceuticals Inc
IPO dateOct 05, 2017
Founded at2013
CEO- -
Number of employees283
Security typeOrdinary Share
Fiscal year-endOct 05
Address222 Berkeley Street
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02116
Phone18572644280
Websitehttps://rhythmtx.com/
Ticker SymbolRYTM
IPO dateOct 05, 2017
Founded at2013
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data